Global Pneumococcal Vaccine Market 2016-2020

This market study report presents a detailed analysis of the key players in the global pneumococcal vaccine market, including vendors like Pfizer, Sanofi, GSK, and Merck. It also provides a comprehensive analysis of the key drivers, trends, and challenges that influence market growth and further segments the market based on geography (the Americas, APAC, and EMEA).

Pneumococcal vaccine market outlook

In terms of volume, the global market for pneumococcal vaccines will grow at a CAGR of over 8% by 2020. The high demand for vaccines with a broad serotype coverage is a critical factor impelling this market’s growth prospects over the next few years. Recently, there has been an increase in pneumococcal diseases because of causative serotype. This serotype shift has created the need for vaccines with broader coverage as the available vaccines are not effective against all serotypes. The seven serotype (4, 6B, 14, 19F, 18C, 23F, 9V) contained in PCV 7 were among the most common causes of invasive pneumococcal disease (IPD) in children aged less than five years.  As a result, the demand for newer pneumococcal vaccines with a broader serotype coverage has increased significantly.

Another eminent factor fostering this market’s growth prospects is the advent of protein-based combination pneumococcal vaccines. At present, numerous new pneumococcal protein-based vaccines are undergoing clinical trial evaluations. These vaccines consist of serotype-independent subunit vaccines, which contain purified proteins and antigens that are expressed by the recombinant bacteria. These vaccines help avoid the problems of serotype replacement by directly targeting proteins that are highly preserved among many pneumococcal serotypes. 

Pneumococcal vaccine market forecasts: Competitive landscape and key vendors

The global pneumococcal vaccine market is competitive and is primarily dominated by the vendor Pfizer. In this market, Pfizer dominates over the other vendors in terms of shares owing to its robust vaccine product, Prevnar, which generated revenues of over USD 6 billion in 2015.

Key vendors in the pneumococcal vaccine market

• Pfizer
• Sanofi
• GSK
• Merck

Pneumococcal vaccine market regions

• Americas
• APAC
• EMEA

During 2015, the Americas dominated this market by accounting for a market share of more than 45%. The market in this region is flourishing owing to the high incidence of pneumococcal infections in the US, which, in turn, results in the increased consumption of pneumococcal vaccines. Moreover, with the increasing use of combination vaccines and the introduction of novel vaccines, this market will have a positive outlook until the end of the forecast period.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global pneumococcal vaccine market?
• What are the key market trends impacting the growth of the global pneumococcal vaccine market?
• What are the challenges to market growth?
• Who are the key vendors in the global pneumococcal vaccine market?
• What are the market opportunities and threats faced by the vendors in the global pneumococcal vaccine market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of global pneumococcal vaccine market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Meningococcal Vaccines Market 2016-2020